{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:56:38Z","timestamp":1793148998379,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.dsx.2023.102849","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:35:18Z","timestamp":1694640918000},"page":"102849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"17","author":[{"given":"Sanjay","family":"Bandyopadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saibal","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambo Samrat","family":"Samajdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank R.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2023.102849_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2023.102849_bib2","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dsx.2023.102849_bib3","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2023.102849_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dsx.2023.102849_bib5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2023.102849_bib6","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2023.102849_bib7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dsx.2023.102849_bib8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: an update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.dsx.2023.102849_bib9","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.dsx.2023.102849_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dsx.2023.102849_bib11","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dsx.2023.102849_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.dsx.2023.102849_bib13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2023.102849_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087488","article-title":"Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease","volume":"9","author":"Bernsmeier","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.dsx.2023.102849_bib15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3389\/fendo.2018.00649","article-title":"Future perspectives on GLP-1 receptor agonists and GLP-1\/glucagon receptor Co-agonists in the treatment of NAFLD","volume":"9","author":"Seghieri","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.dsx.2023.102849_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.phrs.2018.09.025","article-title":"Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"137","author":"Bifari","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.dsx.2023.102849_bib17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1590\/S0004-27302013000900005","article-title":"Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease","volume":"57","author":"Fan","year":"2013","journal-title":"Arquivos Bras Endocrinol e Metabol"},{"key":"10.1016\/j.dsx.2023.102849_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dsx.2023.102849_bib19","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.dsx.2023.102849_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.622589","article-title":"Comparison of the efficacy of glucagon-like peptide-1 receptor agonists in patients with metabolic associated fatty liver disease: updated systematic review and meta-analysis","volume":"11","author":"Dai","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.dsx.2023.102849_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1170881","article-title":"Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.dsx.2023.102849_bib22","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.cgh.2009.06.007","article-title":"Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Hossain","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dsx.2023.102849_bib23","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1053\/j.gastro.2008.09.018","article-title":"Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease","volume":"135","author":"Goessling","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dsx.2023.102849_bib24","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2023.102849_bib25","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2023.102849_bib26","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2011"},{"key":"10.1016\/j.dsx.2023.102849_bib27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2023.102849_bib28","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2023.102849_bib29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.dsx.2023.102849_bib30","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.dsx.2023.102849_bib31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dsx.2023.102849_bib32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jgh3.12780","article-title":"Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: a pilot study","volume":"6","author":"Arai","year":"2022","journal-title":"JGH Open"},{"key":"10.1016\/j.dsx.2023.102849_bib33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.rce.2022.11.007","article-title":"Diabetes, Obesity, and Nutrition Working Group of the Spanish Society of Internal Medicine (SEMI). Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity","volume":"223","author":"Carretero-G\u00f3mez","year":"2023","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.dsx.2023.102849_bib34","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dsx.2023.102849_bib35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"NN9931-4492 investigators. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dsx.2023.102849_bib36","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"NN9931-4296 investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2023.102849_bib37","first-page":"S0168","article-title":"MK-6024 P001 Study Group. A Phase 2a active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dsx.2023.102849_bib38","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.3390\/nu14214673","article-title":"Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study","volume":"14","author":"Volpe","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.dsx.2023.102849_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metabol"},{"key":"10.1016\/j.dsx.2023.102849_bib40","doi-asserted-by":"crossref","first-page":"518","DOI":"10.21037\/hbsn-2021-13","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide","volume":"10","author":"Mantovani","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.dsx.2023.102849_bib41","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dsx.2023.102849_bib42","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.dsx.2023.102849_bib43","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dsx.2023.102849_bib44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of non-alcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dsx.2023.102849_bib45","first-page":"1388","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dsx.2023.102849_bib46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dsx.2023.102849_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.622589","article-title":"Comparison of the efficacy of glucagon-like peptide-1 receptor agonists in patients with metabolic associated fatty liver disease: updated systematic review and meta-analysis","volume":"11","author":"Dai","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.dsx.2023.102849_bib48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.dsx.2023.102849_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01663-y","article-title":"A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)","volume":"11","author":"Ghosal","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.dsx.2023.102849_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1170881","article-title":"Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.dsx.2023.102849_bib51","volume":"14","author":"Gu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dsx.2023.102849_bib52","article-title":"Safety of semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.dsx.2023.102849_bib53","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.dsx.2023.102849_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000705","article-title":"Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in The Netherlands","volume":"7","author":"Hunt","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.dsx.2023.102849_bib55","first-page":"740","article-title":"Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States","volume":"28","author":"Kim","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.dsx.2023.102849_bib56","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1097\/MJT.0000000000001643","article-title":"Evaluating the efficacy and pharmacoeconomics of semaglutide and tirzepatide in the setting of obesity","volume":"30","author":"Nguyen","year":"2023","journal-title":"Am J Therapeut"},{"key":"10.1016\/j.dsx.2023.102849_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102174","article-title":"Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"47","author":"Bandyopadhyay","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.dsx.2023.102849_bib58","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s13300-022-01239-7","article-title":"Additional effect of luseogliflozin on semaglutide in nonalcoholic steatohepatitis complicated by type 2 diabetes mellitus: an open-label, randomized, parallel-group study","volume":"13","author":"Miyake","year":"2022","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.dsx.2023.102849_bib59","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","article-title":"Current therapies and new developments in NASH","volume":"71","author":"Dufour","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.dsx.2023.102849_bib60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD","volume":"107","author":"Patel Chavez","year":"2022","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123001455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123001455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:23:32Z","timestamp":1761729812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402123001455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1871402123001455"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102849","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102849"}}